252 related articles for article (PubMed ID: 26438599)
21. Identification of beta-catenin as a novel substrate of Polo-like kinase 1.
Arai T; Haze K; Iimura-Morita Y; Machida T; Iida M; Tanaka K; Komatani H
Cell Cycle; 2008 Nov; 7(22):3556-63. PubMed ID: 19001871
[TBL] [Abstract][Full Text] [Related]
22. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression.
Yu J; Liu D; Sun X; Yang K; Yao J; Cheng C; Wang C; Zheng J
Cell Death Dis; 2019 Jan; 10(1):26. PubMed ID: 30631044
[TBL] [Abstract][Full Text] [Related]
23. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
24. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
[TBL] [Abstract][Full Text] [Related]
25. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.
Choi M; Kim W; Cheon MG; Lee CW; Kim JE
Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551
[TBL] [Abstract][Full Text] [Related]
26. Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone.
Jiang Y; Dai J; Zhang H; Sottnik JL; Keller JM; Escott KJ; Sanganee HJ; Yao Z; McCauley LK; Keller ET
Mol Cancer Res; 2013 Dec; 11(12):1597-610. PubMed ID: 24088787
[TBL] [Abstract][Full Text] [Related]
27. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Song B; Liu XS; Rice SJ; Kuang S; Elzey BD; Konieczny SF; Ratliff TL; Hazbun T; Chiorean EG; Liu X
Mol Cancer Ther; 2013 Jan; 12(1):58-68. PubMed ID: 23188630
[TBL] [Abstract][Full Text] [Related]
28. Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer.
Jeong SB; Im JH; Yoon JH; Bui QT; Lim SC; Song JM; Shim Y; Yun J; Hong J; Kang KW
Mol Cancer Ther; 2018 Apr; 17(4):825-837. PubMed ID: 29437878
[TBL] [Abstract][Full Text] [Related]
29. 3-methoxyapigenin modulates β-catenin stability and inhibits Wnt/β-catenin signaling in Jurkat leukemic cells.
Chuang KA; Lieu CH; Tsai WJ; Huang WH; Lee AR; Kuo YC
Life Sci; 2013 Apr; 92(12):677-86. PubMed ID: 23333831
[TBL] [Abstract][Full Text] [Related]
30. WNT/β-catenin pathway is modulated in asthma patients and LPS-stimulated RAW264.7 macrophage cell line.
Lee H; Bae S; Choi BW; Yoon Y
Immunopharmacol Immunotoxicol; 2012 Feb; 34(1):56-65. PubMed ID: 21699440
[TBL] [Abstract][Full Text] [Related]
31. Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.
Li Q; Sun M; Wang M; Feng M; Yang F; Li L; Zhao J; Chang C; Dong H; Xie T; Chen J
Cancer Sci; 2021 May; 112(5):1695-1706. PubMed ID: 33605517
[TBL] [Abstract][Full Text] [Related]
32. Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
Luo F; Li J; Liu J; Liu K
Cancer Gene Ther; 2022 Nov; 29(11):1707-1719. PubMed ID: 35750753
[TBL] [Abstract][Full Text] [Related]
33. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
34. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.
Deeraksa A; Pan J; Sha Y; Liu XD; Eissa NT; Lin SH; Yu-Lee LY
Oncogene; 2013 Jun; 32(24):2973-83. PubMed ID: 22890325
[TBL] [Abstract][Full Text] [Related]
35. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling.
Leung JY; Kolligs FT; Wu R; Zhai Y; Kuick R; Hanash S; Cho KR; Fearon ER
J Biol Chem; 2002 Jun; 277(24):21657-65. PubMed ID: 11940574
[TBL] [Abstract][Full Text] [Related]
36. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Li J; Wang R; Schweickert PG; Karki A; Yang Y; Kong Y; Ahmad N; Konieczny SF; Liu X
Cell Cycle; 2016; 15(5):711-9. PubMed ID: 26890815
[TBL] [Abstract][Full Text] [Related]
37. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic Insights into the Selective Dual BET and PLK1 Inhibitory Activity of a Novel Benzamide Compound in Castration-Resistant Prostrate Cancer.
Akawa OB; Subair TI; Omolabi KF; Okunlola FO; Soliman MES
Chem Biodivers; 2021 Dec; 18(12):e2100519. PubMed ID: 34729902
[TBL] [Abstract][Full Text] [Related]
39. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma.
Kadletz L; Bigenzahn J; Thurnher D; Stanisz I; Erovic BM; Schneider S; Schmid R; Seemann R; Birner P; Heiduschka G
Head Neck; 2016 Apr; 38 Suppl 1():E1918-25. PubMed ID: 26713885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]